Henry Ford Hospital Medical Journal
Volume 36

Number 1

Article 10

3-1988

Anticoagulant and Antithrombotic Therapy in Deep Venous
Thrombosis and Pulmonary Embolism
Paul D. Stein

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons

Recommended Citation
Stein, Paul D. (1988) "Anticoagulant and Antithrombotic Therapy in Deep Venous Thrombosis and
Pulmonary Embolism," Henry Ford Hospital Medical Journal : Vol. 36 : No. 1 , 35-40.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol36/iss1/10

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has
been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health
System Scholarly Commons.

Anticoagulant and Antithrombotic Therapy in Deep Venous
Thrombosis and Pulmonary Embolism
Paul D. Stein, MD*

Historical Perspective
he treatment of deep venous thrombosis and pulmonary embolism has been a long and continuing interest of physicians
at Henry Ford Hospital. Heparin was discovered by Jay McLean
in 1916 when he was a student in the laboratory of Dr. W.H.
Howell at Johns Hopkins University (1,2). The anticoagulant
was named heparin because it came from dog's liver (2). Results
of investigations of this heparphosphatid were described by
Howell and Holt in 1918 (3). The use of heparin as an anticoagulant for blood transfusion was explored at Henry Ford
Hospital in 1924 (4), where the prevention of experimentally
produced thrombosis and pulmonary embolism with heparin
was studied (5). At that time, untoward reactions resulted from
the injection of enough heparin to render even small amounts of
blood incoagulable; therefore, full doses, as we use today, were
not given. In 1928, however, heparin was purified sufficientiy to
initiate more extensive use in patients (6). The use of heparin in
the management of thrombosis of veins following injury was reported in 1937 (7). By 1940, 440 patients had been given prophylactic heparin to prevent pulmonary embolism following
various operative procedures (8). McClure and Lam (9) presented their early experience with the use of heparin for the treatment of pulmonary embolism or deep venous thrombosis in 11
patients. By 1941, systemic heparin had been administered to 30
patients at Henry Ford Hospital, and 24 of these patients were
treated because of pulmonary embolism (10). The duration of
treatment was unknown, and at that time two days of treatment
was considered a reasonable period (9). In the early 1940s, oral
anticoagulants with dicumarol became possible. By 1943, the
experience with this dmg, administered on an investigative basis
only, included 637 patients throughout the world (11). Lam (11)
reported results of treatment with dicumarol in 18 patients.
Along with the vast experience obtained with anticoagulants in
subsequent years, a huge amount of literature has been written
on the use of anticoagulants in the prevention and treatment of
deep venous thrombosis and pulmonary embolism. The following is an in-depth review of this subject in an attempt to
crystallize the critical points related to the benefits and risks of
anticoagulant therapy in these conditions.

T

gate incidence obtained from several studies of lower limb
thrombosis in unselected autopsies is 43% (460 of 1,072 patients), and we observed leg vein thrombi in 48% of unselected
patients at autopsy (12). Based upon review of numerous autopsy
studies, the incidence of thrombi in the calves is higher than
in the thighs, and thrombi in the thighs alone are the least common (12).
Numerous anatomic stmctures in the legs have been cited as
sources of pressure causing decreased flow. Examples of such
anatomic stmctures are the soleus muscle which compresses the
posterior tibial vein, the adductor ring which compresses the
popliteal vein, and the inguinal ligament which compresses the
femoral vein. Since stasis is thought to be the single most important factor contributing to thrombosis, the high incidence of
thrombi in these veins may at least in part be accounted for by
these pressure points. Intramuscular veins are particularly dependent on muscular contractions for emptying because they are
thin-walled and tortuous and have no venous impulse. With inactivity they become distended by a stagnant column of blood.
The high incidence of thrombosis found in the intramuscular
veins may be explained by these characteristics.
Valve pockets are frequent sites of thrombus origin. Five of
the six patients in our study who had small (less than 0.5 cm)
thrombi had them within valve pockets, and some of the larger
thrombi could clearly be traced to origins in valve pockets (12).
Clinical venography has demonstrated pooling of contrast
medium at these sites. The eddying of blood with consequent
silting of platelets and leukocytes within these stmctures presumably creates a situation wherein thrombosis is precipitated.
In every case in which the thigh and calf were thrombosed in
continuity, the thrombi in the calf were older than those in the
thigh (12). Histological investigations have shown no distinction
between venous thrombosis in patients who had clinical evidence of inflammation (thrombophlebitis) and those who were
asymptomatic (phlebothrombosis). The presence of a thrombus
can induce inflammation in the underlying wall of the vein,
which in some patients is extensive enough to produce pain,
tenderness, swelling, and fever.
The autopsy incidence of deep venous thrombosis increases
with age (13). The rate of occurrence was 17% among patients

The Problem of Deep Venous Thrombosis
The intensity of prophylactic drugs and procedures for the
prevention of deep venous thrombosis can be tailored to the risk
of its development with consideration of the hazards of bleeding
complications. For this reason, some background regarding the
occurrence of deep venous thrombosis is relevant. The aggre-
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aged 30 to 39 years, 37% in patients aged 40 to 49, and 73% in
octogenarians. Unfortunately, the risk of bleeding with heparin
also increases with age, at least in females (14). Among females
aged 60 or older, 50% had bleeding with heparin, as compared
to younger females or males who had a 10% to 19% incidence
of bleeding.
An impression of the incidence of venous thrombosis in
various clinical circumstances can be obtained by noninvasive
studies, particularly '^-''I-fibrinogen leg scans and impedance
plethysmography (15).
The sensitivity and specificity of the diagnostic test must be
considered in evaluating diagnostic data. Based upon pooled
data reported from several investigators, each ofwhich was cited
by Gallus (15), 91% of patients with abnormal leg scans showed
thrombi identified by venography. This may imply a lack of sensitivity of the venogram or a false-positivefibrinogenscan. Only
2% of patients with normalfibrinogenscans showed abnormal
venograms. Thus, if the leg scan is abnormal, venous thrombosis is likely present.
The incidence of venous thrombosis, particularly of veins of
the thigh, may be even higher than suggested by leg scans. Only
60% of patients with abnormal venograms had abnormal scans,
and 22% of patients with normal venograms showed abnormal
scans (15). Again, this may be interpreted either as false-positive
scans or as scans having more sensitivity than the venograms.
The latter is likely, particularly regarding thrombosis in the
veins of the calves. The venogram, particularly of the calves,
may not be sensitive. Among patients at autopsy in whom we
performed postmortem venograms, in approximately 90% of
the examinations of the veins in the thigh, the venographic impression corresponded to the anatomicfindings(12). However,
filling of the calf veins in general was less adequate. Apparent
filling defects or absence of vessels were unreliable guides to the
presence of thrombosis in the calf veins.
The impedance plethysmogram may relate closer to the
venogram than thefibrinogenleg scan because both the impedance plethysmogram and venogram are more sensitive for the
detection of thrombi of the veins of the thighs than of the
calves. Among 169 abnormal venograms, the impedance
plethysmogram was positive in 92% (16). Among 305 patients
with normal venograms, the impedance plethysmogram was
negative in 96% (16). Among patients with suspected pulmonary embolism and normal impedance plethysmograms, only
10% (two of 20) had pulmonary embolism by angiography (17),
which suggests that the plethysmogram may have some value as
a noninvasive screening test.
Calf vein thrombosis is less likely to lead to pulmonary embolism than thrombosis of the thigh veins. Among 21 patients with
thrombosis of the calf veins, none showed an abnormal ventilation/perfusion scan, whereas if both the calf and thigh veins
were involved, 53% (eight of 15) showed abnormal ventilation/
perfusion scans (18).

Who is at Risk of Deep Venous Thrombosis?
Patients undergoing orthopedic surgery or suffering from
femoral fractures are commonly recognized to have a high risk
of deep venous thrombosis. The extent of risk, however, is strik-
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ing. Among 65 patients with femoral fractures, 43% had deep
venous thrombosis, and pooled data following orthopedic surgery, which included over 1,000 patients among references cited
by Sasahara et al (17), showed a 47% incidence of deep venous
thrombosis. Perhaps even more striking, although based upon
only 63 patients, was a 51% incidence of deep venous thrombosis foflowing thoracic surgery (19). Major surgery is associated with a 25% incidence of deep venous thrombosis (20).
Acute myocardial infarction, when studied by sensitive methods
(fibrinogen leg scan), carries about the same risk (24%) (17).
Childbirth seems to carry a relatively small risk (3%) of deep
venous thrombosis (15).
In evaluating these data it is important to recognize that
fibrinogen scans and impedance plethysmography are sensitive
tests, and the incidence of venous thrombosis may be considerably higher than it would seem based on clinical evaluation.
Signs and symptoms of venous thrombosis occur in only 50% of
patients in whom thefibrinogenscan shows thrombi (21). Also,
only 23% of those patients with abnormal leg scans are shown
by venography to have extension of the thrombus into the veins
ofthe thigh (21). Pulmonary embolism occurred in almost 40%
of the patients when the thigh veins were involved. When only
the calf veins were involved, the risk was minimal (21).

Knowing the Risk of Deep Venous
Thrombosis, What is the Risk, if Untreated,
of Pulmonary EmboUsm?
Few studies directly address this issue, and these are old. The
data .seem compelling, however. Among 347 untreated patients
with clinical evidence of thrombophlebitis, 37% died of
pulmonary embolism (22). The risk of recurrent pulmonary
embolism is equally grim among untreated patients. Among
19 untreated patients with pulmonary embolism, ten (53%)
suffered a recurrent embolism and tive (26%) died (23). The indication for prevention and treatment of thromboembolism,
therefore, is clear.

Prevention of Deep Venous Thrombosis
Low-dose heparin (10.000 to 15,000 units daily, administered
subcutaneously in divided doses) has gained wide acceptance as
prophylaxis for the prevention of deep venous thrombosis,
based upon a multicenter trial of patients undergoing general
surgery including abdominal surgery, genitourinary surgery,
and some orthopedic surgery (but no thoracic surgery) (20).
Among 667 untreated patients and 625 treated patients, the incidence of deep venous thrombosis was reduced from 24.6% to
7.7% with low-dose heparin. This experience seems to be consistent based upon pooled data as reviewed by Sasahara et al
(17). A 25% incidence of deep venous thrombosis was reported
among 1,884 untreated patients, whereas only 6% of 1,790
treated patients suffered deep venous thrombosis (17). In view of
these excellent results, the data have been extrapolated by many
physicians to include prophylaxis of other groups of patients at
risk of deep venous thrombosis and pulmonary embolism (24).
Such intuitive extensions ofthe data may not be valid.
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What About the Use of Low-Dose Heparin
Following Orthopedic Surgery, Thoracic
Surgery, or Medical Conditions?
The data in this regard are less extensive. Among patients
with femoral fractures, a trend suggested some benefit, but the
incidence of deep venous thrombosis remained at high levels despite treatment. Among untreated patients, 43% suffered deep
venous thrombosis, whereas among those treated with low-dose
heparin, 23% had deep venous thrombosis (25). The incidence
of pulmonary embolism following hip surgery or above-theknee amputation was not reduced by low-dose heparin (26).
Similarly, following thoracotomy, low-dose heparin reduced
the incidence of deep venous thrombosis but was not entirely
effective. In such patients, 51% of controls had deep venous
thrombosis and 28% of patients treated with low-dose heparin
developed deep venous thrombosis (19).
Regarding medical indications for prophylaxis against deep
venous thrombosis, heparin has been shown to be beneficial in
patients foflowing acute myocardial infarction. In such subjects,
pooled data indicate that the incidence of deep venous thrombosis was reduced from 24% in the untreated group to 7%
among those who received low-dose heparin (17).
The role of low-dose heparin for the reduction of deep venous
thrombosis following nonhemorrhagic stroke looks promising.
Using low-dose heparin, the occurrence of deep venous thrombosis on leg scans was decreased from 73% to 22% (27). Of the
untreated patients who died. 70% had some pulmonary emboli
at autopsy. Immobilization due to malignant conditions has not
been studied sufficientiy to permit a recommendation regarding
low-dose heparin (28).

Antiplatelet Agents
Antiplatelet agents generally have not been effective for the
prevention of deep venous thrombosis. Several reports suggest
no reduction of deep venous thrombosis with the use of either
aspirin or hydroxychloroquine following general surgery. (Hydroxychloroquine is not currently used, however, as an antiplatelet agent.) Pooled data among both treated and untreated
groups showed a 21% to 23% incidence of deep venous thrombosis (17). Following hip surgery, however, some have shown an
advantageous trend among patients treated with aspirin, with a
45% incidence among untreated patients and a 25% incidence of
deep venous thrombosis among patients treated with aspirin
(29). Alfaro et al (30) found even better results, although with
fewer patients.

TheRoleof Dextran
Dextran inhibits platelet function and fibrin polymerization.
It was not as effective as low-dose heparin for the prevention of
deep venous thrombosis following major surgery, but the incidence was improved over untreated controls (31). The incidence
of deep venous thrombosis in control subjects, those treated
with dextran, and those treated with heparin was 37%, 25%, and
12%, respectively. This experience seems to be confirmed by
pooled data which showed a 22% incidence of deep venous
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thrombosis in control subjects and a 14% incidence among those
treated with dextran (17).
Following orthopedic surgery, a reduction of the incidence of
deep venous thrombosis was suggested by pooled data which
showed a 47% incidence among untreated patients and a 25%
incidence among those who received dextran (17).

Ultralow-Dose Heparin for the Prevention of
Deep Venous Thrombosis
The use of intravenously administered heparin, 1 U/kg/hr,
effectively reduced the occurrence of deep venous thrombosis
among 50 untreated patients (22% incidence) and 45 treated patients (4% incidence) (32). There seem to be no confirmatory
studies of this observation.

The Role of Pneumatic Compression for
Prevention of Deep Venous Thrombosis
Intermittent pneumatic leg compression is thought to activate
the fibrinolytic system as well as prevent stasis. Following general surgery, intermittent pneumatic compression appears effective, reducing the incidence of deep venous thrombosis from
29% to 3% (17). Among patients following neurosurgery, intermittent pneumatic compression reduced the incidence of deep
venous thrombosis from 19% to 1.5% in one study (33) and from
25% to 9% in another (34).

The Risk of Preventive Treatment
Low-dose heparin is contraindicated in patients undergoing
operations on the eye or brain (35). An increased number of
wound hematomas following low-dose heparin in patients undergoing abdominal or thoracic surgery has been reported, but
no differences were noted in the number of deaths attributable to
hemorrhage. Some investigators have observed increased bleeding and wound complications following therapy with low-dose
heparin (36). Thrombocytopenia also has been reported with
low-dose heparin (37,38).
The question of complications with low-dose heparin was addressed in detail in a survey (24). Of the 83 cardiologists and
pulmonary physicians who responded, some were directors of
coronary care or intensive care units at major hospitals and consequently had seen hundreds of patients treated with low-dose
heparin. Most physicians (90%) recalled no complications other
than a rare and clinically unimportant hematoma at the site of
injection. Heparin in low doses, in the absence of a contraindication, therefore, would seem safe. A few physicians, however, have encountered complications. Massive hematomas of
the abdominal wall occurred in two patients. One of these patients also suffered thrombocytopenia induced by heparin.
Wound infection and sepsis developed, and the patient died.
(This was the only reported death related to low-dose heparin.)
Thrombocytopenia was induced by heparin in three other patients. Bleeding from wounds severe enough to require a blood
transfusion occurred in three patients. Bleeding at a distal site,
usually gastrointestinal (some of which may have been secondary to stress ulcers), was observed in six patients. The preva-
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Ience ofthese complications cannot be estimated, but clearly
these were rare occurrences.

Risks of TVeatment of Deep Venous
Thrombosis and Pulmonary Embolism
Treatment of patients with deep venous thrombosis for 12
weeks with warfarin at a prothrombin time of 1.5 to 2 times control after two weeks of treatment with heparin resulted in a recurrence rate of deep venous thrombosis of only 2%, which was
comparable to heparin therapy among patients in whom the partial thromboplastin time was 1.5 to 2 times control (39). Bleeding occurred in 17% of patients treated with warfarin but only in
1% treated with heparin.
Initial heparin requirements are greater and heparin clearance more rapid in patients with deep venous thrombosis
and pulmonary embolism than in controls (40). Following the
same dose of heparin (7,750 units) in controls and patients with
deep venous thrombosis, the partial thromboplastin time was
20 seconds shorter in those with deep venous thrombosis.
More heparin, therefore, was required to maintain the same
therapeutic partial thromboplastin time.
Low-dose heparin (5,000 units every 12 hours) is ineffective
in the treatment of deep venous thrombosis. Among 35 patients
with deep venous thrombosis who were treated for three months
with low-dose heparin, deep venous thrombosis recurred in 23%
and pulmonary embolism occurred in 3% (41). Among 33
patients with deep venous thrombosis who were treated with
warfarin (prothrombin time 1.5 to 2 times control), there was
no recurrence or pulmonary embolism (41). Bleeding complications, however, were greater among patients treated
with warfarin.
The duration of anticoagulant therapy reasonably can be kept
to 12 weeks because thromboembolic complications are relatively infrequent after that time (42). More recent data suggest
that even six weeks of therapy is as effective as more prolonged
therapy in preventing recurrent venous thrombosis or pulmonary embolism (43).
The risk of bleeding with warfarin increases with the duration
of therapy. Some have reported a 10% risk of major bleeding
with 12 weeks, 18% with one year, 26% with two years, and 41%
withfiveyears (43). This is higher than the reported incidence of
bleeding among patients anticoagulated because of myocardial
infarction or prosthetic heart valves. The reported incidence in
such patients ranged from two to 15 per 100 patients per year, and
the incidence of major bleeds was zero to eight per 100 patients
per year (44). Because of the high incidence of bleeding with
intense warfarin therapy, the use of less intense warfarin has
been explored.
In patients undergoing hip and knee replacement, Francis et
al (45) administered warfarin to prolong the prothrombin time to
about 1.1 to 1.2 times control before surgery and kept it at 1.5
times control or less after surgery. This reduced the incidence of
deep venous thrombosis to 21% in comparison to deep venous
thrombosis in patients treated with dextran (51%). In the treatment of patients with deep venous thrombosis, Hull et al (46)
found the same incidence (2%) of recurrent deep venous thrombosis and/or pulmonary embolism with less intense warfarin
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(prothrombin time 1.4 to 2 times control) that they observed with
more intense warfarin (prothrombin time 1.8 times control).
Others also employed a comparable intensity level of warfarin
with success. Deep venous thrombosis was 6% following major
gynecological surgery in patients treated with oral anticoagulants with a prothrombin time equivalent to that of rabbit
brain thromboplastin (1.3 to 1.8 times control) (47). Sevitt and
Gallagher (48), with oral anticoagulants administered to produce a prothrombin time equivalent to that of rabbit brain thromboplastin of 1.3 to 1.5 times control, reduced the incidence of
pulmonary embolism in patients following hip fracture from
18% in controls to zero in treated patients. In the prevention of
recurrent pulmonary embolism. Coon and associates (42), with
less intense warfarin (prothrombin time 1.4 to 1.8 times control),
showed a recurrence of pulmonary embolism of 7%, whereas
with more intense warfarin (prothrombin time 1.9 to 2.8) the
recurrence of pulmonary embolism was 3%.
All reported measurements of the prothrombintimein this review give measurements or equivalent measurements that would be
obtained with a one-stage prothrombin time obtained with rabbit
brain thromboplastin. Hirsh et al (49) described that the prothrombin time measured with rabbit brain thromboplastin (as is typical in
the United States and Canada) would be less prolonged than the
prothrombintimemeasured with human brain thromboplastin (as is
typical in the United Kingdom). A prothrombin time of 2 times
control obtained with human brain thromboplastin is equivalent to a
prothrombin time of 1.2 to 1.3 times control with rabbit brain
thromboplastin. This important difference may have led physicians
in North America to misinterpret reports from the United Kingdom. For example, Sevitt and Gallagher (48), when reporting good
results in the prevention of deep venous thrombosis in patients with
fractures, indicated that they achieved a prothrombin time of 2 to 3
times control using human brain thromboplastin. In the United
States, with rabbit brain thromboplastin, this would be an equivalent prothrombin time of 1.3 to 1.5 times control. If, through
misinterpretation, physicians in the United States achieved a prothrombin time of 2 to 3 times control, it would be as if
Sevitt and Gallagher employed a prothrombintimethat exceeded
safe levels.

Pulmonary Embolism
The risk of fatal pulmonary embolism is greater among patients who have had an episode of pulmonary embolism than in
those with deep venous thrombosis (39). Despite anticoagulant
therapy, fatal recurrent pulmonary embolism occurred in 1% of
those with a previous pulmonary embolism but in only 0.1% of
the patients with deep venous thrombosis and no previous pulmonary embolism.

Recommendations for Prevention of
Venous Thromboembolism
Recommendations of the American College of Chest Physicians—National Heart, Lung, and Blood Institute National
Conference on Antithrombotic Therapy (50) are paraphrased
as foflows:
1. Moderate risk patients (general and gynecological surgery,
medical patients, and presumably thoracic surgery): 5,000 units
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Table
Risks of Developing Deep Venous Thrombosis as Assessed by
'^^-Fibrinogen Leg Scans or Phlebography
No
Treatment

Low-Dose
Heparin

Ultralow
Heparin

LowIntensity
Warfarin

Intermittent
Pneumatic
Compression

Aspirin
Warfarin
Dextran
Orthopedic
6%
surgery
47%
25%
25%
21%
25%
—
—
Femoral
fracture
43%
14%
25%
0%
—
—
—
—
VA
Major surgery
25%
8%
21%
6%
14%
6<:?
—
Neurosurgery
22%
4%
—
—
—
—
—
—
Acute myocardial
infarction
24%
7%
2%.
—
—
—
—
—
Acute stroke
73%
22%
—
—
—
—
—
—
These statistics represent the results either of pooled data or the most substantial references, in the opinion of the author Specific references are in
the text.

of heparin subcutaneously every 12 hours or intermittent pneumatic compression.
2. Patients undergoing neurosurgery, major knee surgery,
or urologic surgery: treatment with intermittent pneumatic
compression.
3. Patients undergoing elective hip surgery: pretreat with
adjusted dose of heparin (activated partial thromboplastin time
in upper half of normal range), or treat with moderate dose of
warfarin (prothrombin time 1.2 to 1.5 times control).
4. Patients undergoing surgery for fractured hip: moderate
dose of warfarin (prothrombin time 1.2 to 1.5 times control).

Comments
The strength of the aforementioned recommendations is clear
from the data presented in the Table, which represent pooled results
from numerous studies, most of which are referenced in the text.
This Table, therefore, serves only as a guideline. It is apparent ffom
the Table that most forms of prophylaxis have some benefit, although the level of protection afforded by each varies with the
clinical circumstances. Therefore, if a particular form of prophylaxis may not be appropriate for an individual patient, any ofthe
various regimens may offer some measure of protection.

Recommendations for the TVeatment of Venous
Thrombosis or Pulmonary Embolism
1. First episode: intravenous heparin or subcutaneous heparin
sufficient to prolong the activated partial thromboplastin time
1.5 to 2 times control.
2. Continue heparin seven to ten days.
3. Overlap with oral anticoagulants at least five days.
4. Continue oral anticoagulants for three months.
5. Maintain warfarin at prothrombin time 1.2 to 1.5 times
control.
If there is a recurrent or continuingriskof deep venous thrombosis or pulmonary embolism, indefinite duration of anticoagulants
is recommended. If only the calf veins are involved, no treatment
may be necessary if serial impedance plethysmography is negative,
or heparin may be administered foflowed by warfarin for six weeks.
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These and future guidelines undoubtedly will be modified as further prospective studies are documented.

Acknowledgment
I thank Dr. Conrad R. Lam for his knowledgeable assistance
in preparation of the historical perspectives.

References
1. McLean J. The thromboplastic action of cephalin. Am J Physiol 1916;
41:250-7.
2. Lam CR. The strange story of Jay McLean, the discoverer of heparin.
Henry Ford Hosp MedJ 1985;33:18-23.
3. Howell WH, Holt E. Two new factors in blood coagulation—Heparin and
pro-antithrombin. AmJ Physiol 1918;48:328-41.
4. Mason EC. The use of heparin in blood transfusion. J Lab Clin Med
1924;10:203-6.
5. Mason EC. Blood coagulation: The production and prevention of experimental thrombosis and pulmonary embolism. Surg Gynecol Obstet 1924;
39:421-8.
6. Howell WH. The purification of heparin and its chemical and physiological reactions. Bull Johns Hopkins Hosp 1928:42:199-206.
7. Murray DWG. Jaques LB, Perrett TS, Best CH. Heparin and thrombosis of
veins following injury. Surgery 1937;2:163-87.
8. Murray DWG. Heparin in surgical treatment of blood vessels. Arch Surg
1940:40:307-25.
9. McClure RD, Lam CR. Experiences in heparin administration. JAMA
1940;114:2085-9.
10. LamCR. Heparin administration. Ann Surg 1941:114:205-11.
11. LamCR. The anti-coagulants—heparin and dicumarol. J Mich State Med
Soc 1943;42:968-72.
12. Stein PD, Evans H. An autopsy study of leg vein thrombosis. Circulation
1967;35:671-81.
13. Havig O. Deep-vein thrombosis and pulmonary embolism—Autopsy
study with multiple-regression analysis of possible risk-factors. Acta Chir
Scand 1977;478(suppl):l-120.
14. Jick H, Slone D, Borda IT, Shapiro S. Efficacy and toxicity of heparin in
relation to age and sex. N Engl J Med 1968;279:284-6.
15. Gallus AS. '--''I-Fibrinogen leg scanning. In; Fratantoni J, Wessler S, eds.
Proceedings of conference on prophylactic therapy of deep vein thrombosis and
pulmonary embolism. Publication (NIH) 76-866. National Heart, Lung, and
Blood Institute and Council on Thrombosis, American Heart Association,
1975:77-99.
16. Hull R, Taylor DW, Hirsh J, et al. Impedance plethysmography: The relationship between venous filling and sensitivity and specificity for proximal vein
thrombosis. Circulation 1978;58:898-902.

Anticoagulant and Antithrombotic Therapy—Stein

39

17. Sasahara AA, Sharma GV, Parisi AF. New developments in the detection
and prevention of venous thromboembolism. Am J Cardiol 1979:43:1214-24.
18. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep
venous thrombosis? Ann Intem Med 1981;94:439-44.
19. Jackaman FR, Perry BJ, Siddons H. Deep vein thrombosis after thoracotomy Thorax 1978;33:761-3.
20. Kakkar VV, Corrigan TP, Fossard DP, et al. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: International multicenter trial. Lancet 1975;2:45-51.
21. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deep-vein thrombosis. Lancet 1969:2:230-2.
22. Byme JJ. Phlebitis: A study of 748 cases at the Boston City Hospital. N
Engl J Med 1955:253:579-86.
23. BarriU DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled .study. Lancet 1960:1:1309-12.
24. Stein PD. Low-dose heparin for prevention of pulmonary embolism and
significance of normal lung scan. Cardiopulmonary Medicine 1982:21:12.
25. Svend-Hansen H, Bremerskov V, Gotrik J, Ostri P. Low-dose heparin in
proximal femoral fractures: Failure to prevent deep-vein thrombosis. Acta
Orthop Scand 1981:52:77-80.
26. Williams JW. Eikman EA. Greenberg SH. et al. Failure of low dose heparin to prevent pulmonary embolism after hip surgery or above the knee amputation. Ann Surg 1978;188:468-74.
27. McCarthy ST, Tumer J, Low-dose subcutaneous heparin in the prevention
of deep-vein thrombosis and pulmonary emboli following acute stroke. Age
Aging 1986;15:84-8.
28. Wessler S, Gitel SN, Heparin: New concepts relevant to clinical use.
Blood 1979;53:525-44.
29. Harris WH, Salzman EW, Athanasoulis CA. Waltman AC. DeSanctis
RW. Aspirin prophylaxis of venous thromboembolism after tolal hip replacement. N Engl J Med 1977:297:1246-9.
30. Alfaro MJ, Paramo JA, Rocha E, Prophylaxis of thromboembolic disease
and platelet-related changes following total hip replacement: A comparative
study of aspirin and heparin-dihydroergotamine, Thromb Haemost
1986:56:53-6.
31. Macintyre MC. Vasilescu C, Jones DRB. et al. Heparin versus dextran in
the prevention of deep-vein thrombosis: A multi-unit controlled study. Lancet
1974;2:118-20.
32. Negus D. Cox SJ, Friedgood A. Peel ALG, Wells BW. Ultra-low dose
intravenous heparin in the prevention of postoperative deep-vein thrombosis.
Lancet 1980;1:891-4.
33. Turpie AGG, Gallus AS. Beattie WS, Hirsh J. Prevention of venous
thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf Neurology 1977;27:435-8.
34. Skillman JJ, Collins REC, Coe NP. et al. Prevention of deep vein throm-

40

Henry Ford Hosp Med J—Vol 36, No 1, 1988

bosis in neurosurgical patients: A controlled, randomized trial of extemal pneumatic compression boots. Surgery 1978:83:354-8.
35. Council on Thrombosis, American Heart Association. Prevention of venous thromboembolism in surgical patients by low-dose heparin. Circulation
1977;55;423A-6A.
36. Pachter HL, Riles TS. Low dose heparin—bleeding and wound complications in the surgical patient: A prospective randomized study. Ann Surg
1977;186:669-74.
37. Gallus AS, Goodall KT. Beswick W. Chesterman CN. Heparin-associated thrombocytopenia: Case report and prospective study. Aust NZ J Med
1980;10:25-31.
38. Hrushesky W. Thrombocytopenia induced by low-dose subcutaneous
heparin. Lancet 1977;2:1286.
39. Hull R. Delmore T, Carter C. et al. Adjusted subcutaneous heparin versus
warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med
1982:306:189-94.
40. Beaver BL. Young D, Satiani B. Prediction of heparin requirements in
acute thromboplastic venous disease. Arch Surg 1985;120:436-8.
41. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose
heparin in the long-term treatment of venous thrombosis. N Engl J Med
1979;301:855-8.
42. Coon WW. Willis PW III, Symons MJ. Assessment of anticoagulant
treatment of venous thromboembolism. Ann Surg 1969:170:559-68.
43. Petitti DB. Strom BL. Melmon KL. Duration of warfarin anticoagulant
therapy and the probabilities of recurrent thromboembolism and hemorrhage.
AmJ Med 1986:81:255-9.
44. Levine MN, RaskobG, Hirsh J. Hemorrhagic complications of long-term
anticoagulant therapy Chest 1986;89(suppl):I6S-25S.
45. Francis CW, Marder VJ, McCollister-Evarts C. Yaukoolbodi S. Two-step
warfarin therapy: Prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983;249:374-8.
46. Hull R. Hirsh J. Jay R, et al. Different intensities of oral anticoagulant
therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;
307:1676-81.
47. Tabemer DA, Poller L, Burslem RW, Jones JB. Oral anficoagulants controlled by the British comparative thromboplastin versus low-dose heparin in
prophylaxis of deep vein thrombosis. Br Med J [Clin Resj 1978;1:272-4.
48. Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary
embolism in injured subjects: A trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur Lancet
1959:2:981-9.
49. Hirsh J, Deykin D, Poller L. "Therapeutic range" for oral anticoagulant
therapy Chest 1986;89(suppl):llS-5S.
50. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1986;89(suppl):26S-35S.

Anticoagulant and Antithrombotic Therapy—Stein

